Response to letter entitled: 'Re: Hematological immune related adverse events after treatment with immune checkpoint inhibitors'

Affiliations

¹ Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany; Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. Electronic address: lucie.heinzerling@med.uni-muenchen.de.
² II. Med. Klinik, Onkologie, Hämatologie, Immunologie, Infektiologie, Palliativmedizin Schwarzwald-Baar-Klinikum, Villingen-Schwenningen, Germany.
³ Department of Dermatology, Mühlenkreiskliniken AöR, Ruhr University Bochum Campus, Minden, Germany.
⁴ Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
⁵ Paul-Ehrlich Institut, Langen, Germany.
⁶ Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany.

Comment

Lucie Heinzerling et al. Eur J Cancer. 2021 Aug.

. 2021 Aug:153:272-273.

doi: 10.1016/j.ejca.2021.05.028. Epub 2021 Jun 18.

¹ Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany; Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. Electronic address: lucie.heinzerling@med.uni-muenchen.de.
² II. Med. Klinik, Onkologie, Hämatologie, Immunologie, Infektiologie, Palliativmedizin Schwarzwald-Baar-Klinikum, Villingen-Schwenningen, Germany.
³ Department of Dermatology, Mühlenkreiskliniken AöR, Ruhr University Bochum Campus, Minden, Germany.
⁴ Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
⁵ Paul-Ehrlich Institut, Langen, Germany.
⁶ Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany.

No abstract available

Conflict of interest statement

Conflict of interest statement The authors declare no conflict of interest.

Hematological immune related adverse events after treatment with immune checkpoint inhibitors.
Kramer R, Zaremba A, Moreira A, Ugurel S, Johnson DB, Hassel JC, Salzmann M, Gesierich A, Weppler A, Spain L, Loquai C, Dudda M, Pföhler C, Hepner A, Long GV, Menzies AM, Carlino MS, Sachse MM, Lebbé C, Baroudjian B, Enokida T, Tahara M, Schlaak M, Hayani K, Bröckelmann PJ, Meier F, Reinhardt L, Friedlander P, Eigentler T, Kähler KC, Berking C, Zimmer L, Heinzerling L. Kramer R, et al. Eur J Cancer. 2021 Apr;147:170-181. doi: 10.1016/j.ejca.2021.01.013. Epub 2021 Mar 9. Eur J Cancer. 2021. PMID: 33706206
Re: Hematological immune related adverse events after treatment with immune checkpoint inhibitors: Immune checkpoint inhibitor-related haemophagocytic lymphohistiocytosis.
Grewal US, Thotamgari SR, Shah PR, Uppal JK, Gaddam SJ. Grewal US, et al. Eur J Cancer. 2021 Aug;153:270-271. doi: 10.1016/j.ejca.2021.04.046. Epub 2021 Jun 18. Eur J Cancer. 2021. PMID: 34148729 No abstract available.